Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma

被引：3
|
作者：
Sheikh, Semira [1 ]
Mokhtari, Sepideh [2 ]
Silverman, Jeffrey A. [3 ]
Reid, Kayla [4 ]
Faramand, Rawan [5 ]
Davila, Marco L. [6 ]
Franke, Norman [7 ]
Locke, Frederick L. [6 ]
Jain, Michael D. [6 ]
Wong, Daniel [8 ]
Kuruvilla, John G. [7 ]
机构：
[1] Univ Hlth Network, Div Med Oncol & Hematol, Toronto, ON M5G 2C1, Canada
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Neurooncol, Tampa, FL USA
[3] North York Gen Hosp, Dept Hematol, Toronto, ON, Canada
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol, Tampa, FL USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunol, Tampa, FL USA
[7] Princess Margaret Hosp, Div Med Oncol & Hematol, Toronto, ON, Canada
[8] North York Gen Hosp, Dept Neurol, Toronto, ON, Canada
来源：
EJHAEM | 2022年 / 3卷 / 01期
关键词：
CAR T cell therapy; ICANS; neurotoxicity; transverse myelitis; NEUROTOXICITY;
D O I：
10.1002/jha2.286
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：223 / 227
页数：5
相关论文
共 50 条
  • [31] Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
    Zhang, Wen-ying
    Liu, Yang
    Wang, Yao
    Nie, Jing
    Guo, Ye-lei
    Wang, Chun-meng
    Dai, Han-ren
    Yang, Qing-ming
    Wu, Zhi-qiang
    Han, Wei-dong
    GENE THERAPY, 2018, 25 (03) : 198 - 204
  • [32] A Refractory B-ALL Patient Relapsed with Leukemia Cells Expressing CD19 and Anti-CD19 CAR Gene 14 Days after CR from Anti-CD19 CAR T-Cell Therapy
    Liu Meijing
    Cui, Rui
    Mu, Juan
    Yuan, Ji-Jun
    Mou, Nan
    Yang, Zhen-xing
    Jiang Yan-yu
    Meng Juanxia
    Deng, Qi
    BLOOD, 2019, 134
  • [33] Germline Determinants of Toxicity and Efficacy in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 Autologous CAR T-Cell Therapy
    Strati, Paolo
    Brandt, Amanda
    Henderson, Jared
    Westin, Jason
    Nastoupil, Loretta J.
    Al Zaki, Ajlan
    Jallouk, Andrew P.
    Adkins, Sherry
    Shpall, Elizabeth J.
    Kebriaei, Partow
    Ramdial, Jeremy
    Saini, Neeraj Y.
    Ahmed, Sairah
    Flowers, Christopher R.
    Neelapu, Sattva S.
    Hildebrandt, Michelle
    BLOOD, 2023, 142
  • [34] Overcoming resistance to anti-CD19 CAR T-cell therapy in B-cell malignancies
    Yang, Xingcheng
    Wei, Jia
    Zhou, Jianfeng
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (05) : 821 - 834
  • [35] Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis
    Di Blasi, Roberta
    Le Gouill, Steven
    Bachy, Emmanuel
    Cartron, Guillaume
    Beauvais, David
    Le Bras, Fabien
    Gros, Francois-Xavier
    Choquet, Sylvain
    Bories, Pierre
    Feugier, Pierre
    Casasnovas, Olivier
    Bay, Jacques Olivier
    Mohty, Mohamad
    Joris, Magalie
    Gastinne, Thomas
    Sesques, Pierre
    Tudesq, Jean-Jacques
    Vercellino, Laetitia
    Morschhauser, Franck
    Gat, Elodie
    Broussais, Florence
    Houot, Roch
    Thieblemont, Catherine
    BLOOD, 2022, 140 (24) : 2584 - 2593
  • [36] Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
    Wen-ying Zhang
    Yang Liu
    Yao Wang
    Jing Nie
    Ye-lei Guo
    Chun-meng Wang
    Han-ren Dai
    Qing-ming Yang
    Zhi-qiang Wu
    Wei-dong Han
    Gene Therapy, 2018, 25 : 198 - 204
  • [37] Predicting Outcomes following Anti-CD19 CAR T Cell Therapy in Aggressive B Cell Lymphomas
    Ho, Carrie
    Svoboda, Jakub
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 195 - 196
  • [38] Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study
    Tun, Aung M.
    Patel, Romil D.
    St-Pierre, Frederique
    Ouchveridze, Evguenia
    Niu, Alex
    Thordardottir, Thorunn
    Obasi, Jennifer
    Rosenthal, Allison
    Pophali, Priyanka A.
    Fenske, Timothy S.
    Karmali, Reem
    Ahmed, Sairah
    Johnston, Patrick B.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (09) : 1712 - 1720
  • [39] Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma
    Liu, Wei
    Huang, Wenyang
    Lv, Ryu
    Deng, Shuhui
    Yi, Shuhua
    Liu, Huimin
    Lv, Lulu
    Qiu, Lugui
    Zou, Dehui
    Wang, Jianxiang
    BLOOD, 2020, 136
  • [40] Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma
    Oliai, Caspian
    de Vos, Sven
    BLOOD, 2019, 134
12345